Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patients who have >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period are not eligible Patient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Grade 2 peripheral neuropathy or higher or grade 1 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy or neuropathy with pain, regardless of grade that is seen on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening period Peripheral neuropathy ? grade 3 on clinical examination or grade 2 with pain during the screening period Peripheral neuropathy > grade 2 or > grade 1 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of any cause on clinical examination during the Screening period. Peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening period Patient has greater than or equal than grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period Patient has >= grade 2 neuropathy, sensory, with or without pain, motor, or autonomic, on clinical examination during the screening period Grade >= 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period Peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening period Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period. Patient has ? grade 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination during the screening period Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening period Patient has >= grade 3 peripheral neuropathy, or >= grade 2 with pain on clinical examination during the screening period Peripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapy Peripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapy Patient has >= grade 1 peripheral neuropathy with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Participant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapy Patient has > grade 2 peripheral neuropathy on clinical examination during the screening period Participant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapy Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 2 peripheral neuropathy on clinical examination within 28 days of signing consent Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has grade 3 peripheral neuropathy or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 peripheral neuropathy with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening Peripheral neuropathy >= grade 2 on clinical examination during the screening period Patient with >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period No grade 2 or higher neuropathy Patients with grade 2 or higher peripheral neuropathy will be excluded in the dose escalation phase of the protocol ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not have grade 3 or higher peripheral neuropathy ELIGIBILITY CRITERIA - PHASE II (ARM D): Patients must not have grade 3 or higher peripheral neuropathy Patients with peripheral neuropathy of grade 2 or higher Grade 2 or higher peripheral neuropathy at screening Grade 1 or higher CNS hemorrhage on baseline brain MRI, or history of grade 2 or higher CNS hemorrhage within 12 months Uncontrolled Grade 3 or higher infection Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE Active esophagitis grade B or higher Patients with grade 2 or higher neuropathy Patients must not have Grade 2 or higher peripheral neuropathy. Grade 2 or higher pneumonitis Grade 3 or higher peripheral neuropathy No symptoms attributable to grade 2 or higher peripheral neuropathy Patients with grade 2 or higher peripheral neuropathy are excluded CTCAE grade 3 or higher peripheral neuropathy Patients with persistent grade 3 or higher prior vincristine (VCR) (vincristine sulfate)-related neuropathy Current grade 2 or higher peripheral neuropathy Grade 2 or higher peripheral neuropathy. More than one grade 2 or higher transaminase elevation Patients with grade 2 or higher peripheral neuropathy participants with Grade 2 or higher residual toxicities from prior therapy (including Grade 2 or higher peripheral neuropathy or any grade neuropathy with pain; excluding alopecia). This includes recovery from any major surgery. Note: Participants with planned surgical to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery. Grade 2 or higher persisting prior treatment-related neuropathy Grade 2 or higher peripheral neuropathy Paclitaxel arm: grade 2 or higher neuropathy Grade 2 or higher peripheral neuropathy. Grade 2 or higher peripheral neuropathy per NCI CTCAE Grade 2 or higher peripheral neuropathy Patients must not have grade 2 or higher peripheral neuropathy Active Grade 3 or higher infection. Patients who have had grade 2 or higher peripheral neuropathy within 14 days prior to registration are not eligible (must have resolved to grade 1 or lower to register) Peripheral neuropathy or neuropathic pain Grade 2 or higher Neuropathy grade 2 or higher Grade 2 or higher peripheral neuropathy (paclitaxel arm only) Grade 2 or higher neuropathy (CTCAE V4.0) Subjects with T3 or higher, and N3 disease Current grade II or higher peripheral neuropathy. Significant peripheral neuropathy defined as grade 2 or higher Current grade II or higher peripheral neuropathy. Peripheral neuropathy that is grade 2 or higher Grade 3 or higher peripheral neuropathy Grade 2 or higher peripheral neuropathy per NCI CTCAE Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1 Grade 2 or higher neuropathy Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to the first dose of study drug Current grade 3 or higher neuropathy Grade 2 or higher peripheral neuropathy Grade 2 or higher peripheral neuropathy at the time of study entry Grade 2 or higher oral mucositis Grade 2 or higher peripheral neuropathy Grade II or higher neuropathy Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug Platelets >= 100,000/mm^3, equivalent to CTCAE v 3.0 grade 0-1 Bilirubin =< 1.5 x ULN (CTCAE v 3.0 grade 1) Recovered to ? grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks earlier. Presence of ? CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior cancer therapy Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0 Ongoing adverse effects from prior systemic treatment > NCI CTCAE Grade 1 (with the exception of Grade 2 alopecia) Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade 2 or prolongation of the QTcF interval to >480 msec. Presence of ? CTCAE grade 2 toxicity (except alopecia and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior cancer therapy. Ongoing infection > grade 2 NCI-CTCAE v4.0 Any Grade >1 (according to the NCI CTCAE 4.03) adverse reaction unresolved from previous treatments and not readily managed and controlled with supportive care. Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 4.03). Any ongoing cardiac dysrhythmias of National Cancer Institute (NCI) CTCAE grade > 2, NCI CTCAE grade 4 atrial fibrillation, or corrected QC interval per Fridericia's formula (QTcF) interval > 470 msec, except for documented right bundle branch block, at screening History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0 Significant recent bleeding history defined as NCI CTCAE grade ?2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury) Any history of CTCAE grade ?2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety. Ongoing infection > grade 2 NCI-CTCAE v4.0 Ongoing infection > grade 2 NCI-CTCAE version (v) 4.0 Patients cannot have experienced a significant (CTCAE Grade 3 or 4 with or without neutropenia) infection within 2 weeks of their first dose of MT-3724. Serum bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1) Have Grade 3 or 4 peripheral neuropathy per NCI-CTCAE Version 4.0. Subject has symptomatic cardiac disorders (CTCAE v. 4.03 Grade 3 and 4) Afebrile (<38°C per CTCAE v4.03); Patient has not recovered from toxicity from prior immune checkpoint inhibitor therapy. Recovery is defined as ? NCI-CTCAE Grade 1, except for liver function test levels which must be NCI CTCAE grade 3 serum potassium NCI-CTCAE version 4.03 Grade <2; serum calcium NCI-CTCAE version 4.03 Grade <2; serum magnesium NCI-CTCAE version 4.03 Grade <2; Evidence of peripheral neuropathy > grade 1 by NCI-CTCAE version 4.03; Ongoing infection > grade 2 NCI-CTCAE v4.0 Subjects with baseline symptoms of fever and/or cough and/or shortness of breath and/or wheezing and/or fatigue grade >= 2 (CTCAE version [v]4.0) Patients with hypertriglyceridemia defined as >1000 mg/dL (CTCAE Grade 4). Otherwise, all toxicity at study entry < Grade 1 by NCI CTCAE v4.00 (Patients with ? Grade 2 neuropathy are eligible). Grade 3-4 electrolyte abnormalities (CTCAE v 4.03) except sodium, which must be ?126 mmol/L. Serum creatinine =< 1.5 X ULN (CTCAE grade 1 baseline) Patients who have active clinically serious infection > CTCAE grade 2 are not eligible Serum creatinine =< 1.5 x ULN (CTCAE grade 1 baseline) Patients exhibiting baseline grade 3 or 4 by CTCAE criteria are excluded Ongoing infection > Grade 2 NCI-CTCAE v 4.03 Creatinine less than 1.5 x ULN (CTCAE Grade 1) Bilirubin less than 1.5 x ULN (CTCAE Grade 1) Bilirubin less than or equal to 1.5 x ULN (CTCAE v4 grade 1) Cardiac dysrhythmias of NCI CTCAE grade >= 2 within the last 28 days Serious uncontrolled infection > grade 2 (CTCAE v4.0) Serious uncontrolled infection > grade 2 (CTCAE v4.0) At least one clinical symptom probably or definitely attributed to KSHV-MCD\r\n* Intermittent or persistent fever for at least 1 week (> 38 Celsius degree [C])\r\n* Fatigue (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or greater)\r\n* Gastrointestinal symptoms (includes nausea and anorexia) (CTCAE grade 1 or greater)\r\n* Respiratory symptoms (includes cough and airway hyperreactivity) (CTCAE grade 1 or greater) Clinical relevant AEs or laboratory results related to previous anti-neoplastic therapy have not resolved to a NCI-CTCAE grade ?1. Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0) Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0) Subjects with neuropathy grade ?2 based on CTCAE v4.03 at the time of study entry Presence of any CTCAE grade 2 or greater toxicity Ongoing infection > grade 2 NCI-CTCAE v4.0 Recovery to baseline or ? Grade 1 CTCAE ver.4.0 Patients with ataxia >= CTCAE grade 2 are ineligible Grade 3-4 electrolyte abnormalities (CTCAE, v. 4): Triglycerides < CTCAE grade 2 Subjects who have an active clinically serious infection of CTCAE grade >= 2 Bilirubin less than or equal to 1.5 x ULN (CTEP CTCAE version 4.0, grade 1) Ongoing acute adverse effects from prior anticancer or investigational therapy > NCI CTCAE Grade 1 Serum creatinine ? 1.5 X ULN (CTCAE Grade 1 baseline) Ongoing clinical adverse events NCI CTCAE Grade >2 resulting from prior cancer therapies All prior treatment- related toxicities must be CTCAE (Version 4.0) <=Grade 1 (except alopecia and peripheral neuropathy) at the time of treatment allocation [NCI-CTCAE, 2009]. Neuropathy >NCI-CTCAE Grade 1. Evidence of significant CNS haemorrhage i.e. CTCAE grade 2 or above; All AEs resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to at least NCI-CTCAE (v. 4.03) Grade 1 (except for laboratory parameters outlined below). Ongoing infection > grade 2 NCI-CTCAE v 4.0 Ongoing infection > Grade 2 NCI-CTCAE v4.03. Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0 Presence of ? CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior therapy. Presence of NCI CTCAE ? grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? NCI CTCAE grade 3) due to prior cancer therapy Subjects with known Gilbert's syndrome who have serum bilirubin ? 3 x ULN (NCI CTCAE v4.03 Grade 2) may be enrolled. Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< 1 except neuropathy Ongoing infection > grade 2 NCI-CTCAE v4.0 ? CTCAE Grade 3 anemia, OR ? CTCAE Grade 3 hematoma (bleed) CTCAE v4.0 grade 3 or 4 anorexia or nausea related to metastatic disease. Clinically significant bleeding NCI-CTCAE version 4.0 Grade 3 or higher within 30 days before randomization. Current NCI CTCAE (Version 4.0) Grade >/= 2 peripheral neuropathy Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0 Bilirubin =< 1.5 x ULN, CTCAE grade 1 Serum albumin greater or equal to 3 g/dl (CTCAE 4.0 grade 1 abnormality is acceptable) Serum electrolytes within normal limits (CTCAE 4.0 grade 1 abnormality is acceptable) Resolved acute effects of any prior therapy to baseline severity or Grade ?1 NCI CTCAE. Any toxicity from prior chemotherapy has resolved or Grade 1 (NCI-CTCAE, Version 4.0) Ongoing infection > Grade 2 NCI-CTCAE v4.0. Subject has an ongoing toxicity ? Grade 2 (NCI CTCAE Version 4.03) attributable to prior medication to treat solid tumor (except alopecia) at screening. Has peripheral neuropathy ? Grade 2 (NCI-CTCAE) Active, clinically serious infections of NCI CTCAE v4.0 Grade 2 or higher within 4 weeks prior to Cycle 1, Day 1 Subject has an ongoing toxicity greater than or equal to grade 3 (NCI CTCAE version 4.03) attributable to prior NSCLC treatment at the time of screening. Bilirubin less than or equal to 1.5 x ULN (CTCAE v4.0 grade 1) Ongoing infection > grade 2 NCI-CTCAE v4.0 Signs of peripheral neuropathy (PN) ? NCI CTCAE Grade 2. Signs of peripheral neuropathy (PN) ? NCI CTCAE Grade 2. Anxiety ? CTCAE grade 3 Patients with active clinically serious infections defined as >= grade 2 according to NCI CTCAE, version 4.0 Subjects with valvular heart disease CTCAE (version 4.0) grade 2 Any peripheral neuropathy ? NCI CTCAE Grade 2. ? CTCAE Grade 3 anxiety. Symptomatic peripheral neuropathy grade ?2 NCI CTCAE v4.0. Diarrhoea CTCAE v4.03 Grade ? 2 Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as ?Grade 2 according to NCI CTCAE, version 4.0, or uncontrolled hypertension History of bronchopulmonary hemorrhage NCI CTCAE >/= Grade 2 within 2 months prior to randomization Evidence of CNS hemorrhage CTCAE ? grade 2 on baseline MRI. NCI CTCAE (version 4.03) Grade 3 or higher toxicities due to prior therapy that have not shown improvement and are considered to interfere with current study medication Active clinically serious infections defined as >= Grade 3 according to NCI CTCAE CTCAE Grade 2 or 3 fatigue. Any >=Grade 2 hypophosphatemia (per CTCAE v4.0) at the time of enrolment Active clinically serious infection > NCI-CTCAE grade 2 ? CTCAE grade 3 anxiety Active clinically serious infection > CTCAE v 4.0 grade 2 Active clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0) follicular lymphoma (NCI CTCAE grade 1 or 2) Ongoing infection > CTCAE grade 2 Baseline alopecia (defined CTCAE v4.0 grade > 0) Ongoing infection > grade 2 NCI-CTCAE v4.0 AST > 2.5 x ULN (CTCAE grade 2) Bilirubin > 1.5 x ULN (CTCAE grade 2) Presence of neuropathy > Grade 1 per NCI CTCAE version 5.0 Current alopecia grade 2 or greater as per NCI-CTCAE v.4.0, or significant hair loss or hair breakage Hepatic toxicity >= grade 2 (using CTCAE version 4 standard definitions) Ongoing cardiac dysrhythmias of NCI CTCAE Grade ? 2, uncontrolled atrial fibrillation of any grade, or an average of triplicate QTc interval >470 msec. Not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade <=1 or baseline. Serum lipase ? 2 x ULN i.e. equivalent to ? Grade 2 NCI-CTCAE v.4.03 For Adjuvant Treatment: All AEs resulting from surgery must have resolved to NCI-CTCAE (v. 4.03) Grade ? 1 If applicable, patient with >= grade 2 peripheral neuropathy within 14 days before enrollment Grade 3 peripheral neuropathy within 14 days before enrollment. > Grade 1 peripheral neuropathy within 14 days before enrollment. Patient with peripheral neuropathy Grade >2 Patient has >= grade 2 peripheral neuropathy within 14 days of trial enrollment Patient has >= grade 2 peripheral neuropathy within 14 days before enrollment and at D60-180 after AHCT; patients who had >= grade 2 peripheral neuropathy within 14 days before enrollment but resolves to grade 1 or lower peripheral neuropathy at D60-D180 after AHCT can be enrolled at this time Patient has >= grade 2 peripheral neuropathy Patient has >= grade 2 peripheral neuropathy The patient has peripheral neuropathy >= grade 2 Patient has >= grade 2 peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy within 14 days before enrollment Grade >= 2 peripheral neuropathy within 21 days before enrollment Patient must not have >= grade 2 peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy Patient has >= grade 2 (CTCAE v 4.0) peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy within 14 days before enrollment Patient has > = Grade 2 peripheral neuropathy within 14 days before enrollment. Subject has > grade 2 peripheral neuropathy within 14 days before enrollment Grade >= 2 peripheral neuropathy within 14 days before enrollment Patient has >/= Grade 2 peripheral neuropathy within 14 days before enrollment. No grade 2 >= peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy If applicable, patient has >= Grade 2 peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy If applicable, patient has >= grade 2 peripheral neuropathy within 14 days before enrollment Patient has >= grade 2 peripheral neuropathy within 14 days prior to treatment initiation Patients with grade 3 ataxia or grade >1 extrapyramidal movement disorder are not eligible Any grade I DCIS Any grade II DCIS without comedonecrosis Grade II DCIS with comedonecrosis Patients with a history of Grade 3-4 capillary leak syndrome, or non-cardiac Grade edema are ineligible, e.g., related to SL-401 or other etiology Note: Subjects with ? Grade 2 neuropathy or ? Grade 2 alopecia are an exception to this criterion and may qualify for the study. Ongoing adverse event from previously administered systemic anti-cancer therapy unless has recovered to =< grade 1 or at baseline prior to C1D1\r\n* Subjects with any grade alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the study Must not have experienced any ? Grade 3 AE nor any neurologic or ocular AE of any grade while receiving prior checkpoint inhibitors. Residual side effects to previous therapy > grade 1 prior to randomization (Alopecia any grade and/or neuropathy grade 2 without pain are permitted) Grade 3b FL Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment Presence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol >/=Grade 2; Hypertriglyceridemia >/=Grade 2; Hyperglycemia (fasting) >/=Grade 2; Grade >/=2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 1 without pain are permitted) Ongoing Grade >1 proliferative or nonproliferative retinopathy. Ongoing severe graft-versus-house disease (GVHD) with Grade ?2 serum bilirubin, Grade ?3 skin involvement, or Grade ?3 diarrhea at the start of study therapy. All acute toxic effects of any prior antitumor therapy resolved to ?Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or neurotoxicity [Grade 1 or 2 permitted], or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions as noted below]). Hospitalized patients (or willing to be hospitalized for 24 hours after Rx) with Modified WHO Grade 1 (subset) or Grade 2 Bleeding Score or at risk for same within 4 weeks of screening. The Grade 1 subset includes patients who have either epistaxis, hematuria, oral petechiae, or bleeding at invasive or other wound sites. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, Any Grade, N0, M0 High risk RCC: pT4, Any Grade N0, M0; pT, Any stage, Any Grade, N+, M0 History of grade >= 2 radiation proctitis Peripheral neuropathy > grade 1, except for grade 2 without limitations on instrumental daily life activities; Residual side effects to previous therapy > grade 1 prior to initiation of therapy (alopecia any grade and/or neuropathy grade 2 without pain are permitted) Patients with carcinosarcoma, mucinous, low grade endometrioid, or low grade serous histology evident on pretreatment biopsy Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis Grade 3 or above neuropathy induced from prior treatment, that is not resolved to grade 2 or below despite best supportive care Patients will be excluded if they currently have the following risk factors for retinal vein occlusion (RVO): (1) uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg (2) serum cholesterol >= grade 2 (3) hypertriglyceridemia >= grade 2 (4) hyperglycemia (fasting) >= grade 2 Patients will be excluded from study participation if they currently are known to have any of the following risk factors for RVO: a. Glaucoma with intraocular pressure >= 21 mmHg b. Grade >= 2 serum cholesterol c. Grade >= 2 hypertriglyceridemia d. Grade >= 2 or symptomatic hyperglycemia (fasting) e. Grade >= 2 uncontrolled hypertension (patients with a history of hypertension controlled with anti-hypertensive medication to grade =< 1 are eligible Patients who have residual toxicities > grade 2 attributed to taxane therapy, except for neuropathy, who are excluded if > grade 1 Subjects with low grade tumors (histologic grade 1/3) PRIOR TO LYMPHODEPLETION: For grade 4 neutropenia, ? grade 3 febrile neutropenia, or grade 4 thrombocytopenia, hold bendamustine until toxicity resolve to ? grade 2 The risk factor for RVO are listed below; exclusion should be considered by clinical discretion if they have the following conditions:\r\n* Uncontrolled glaucoma with intra-ocular pressures > 21 mmHg\r\n* Serum cholesterol >= grade 2\r\n* Hypertriglyceridemia >= grade 2\r\n* Hyperglycemia >= grade 2 Evidence of > grade 1 central nervous system (CNS) hemorrhage or > grade 3 venous thromboembolism FIGO grade 1 or 2 endometrioid cancer Subjects who are receiving any concurrent investigational or conventional agent with known or suspected activity against multiple myeloma, or those whose adverse events due to agents administered more than 4 weeks earlier have not recovered to a severity of grade 0 or grade 1; subjects with chronic grade 2 toxicities may be eligible per discretion of the investigator and M. D. Anderson Cancer Center (MDACC) Investigational New Drug (IND) Office (eg, grade 2 chemotherapy-induced neuropathy) COHORT I: Non-bevacizumab failure, i.e. either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen, such as:\r\n* >= grade 3 hypertension not controlled by medication, hypertensive crisis, or hypertensive encephalopathy\r\n* >= grade 3 proteinuria that does not resolve or nephrotic syndrome\r\n* Any grade gastrointestinal (GI) perforation\r\n* >= grade 3 infusion-related reaction\r\n* >= grade 3 wound healing complications\r\n* >= grade 3 hemorrhage or any grade central nervous system (CNS) hemorrhage or >= grade 2 hemoptysis\r\n* Any grade arterial thromboembolic event (e.g. myocardial infarction or cerebral infarction) or >= grade 3 venous thromboembolic event\r\n* Any grade posterior reversible encephalopathy syndrome (PRES)\r\n* >= grade 3 congestive heart failure\r\n* >= grade 2 non-GI abscesses and fistulae AT THE TIME OF INFUSION: Recurrent or refractory HER2-positive GBM\r\n* Immunohistochemistry (IHC) or reverse transcriptase-polymerase chain reaction (RT-PCR) will be used to determine HER2 positivity; results will be compared to standard controls; HER2 expression in tumors on IHC should be ? grade 1 and ?1+ intensity score; wherein grades are defines as: grade 0: no staining; grade 1: 1-25%; grade 2: 26-50% and grade 3: 51-100% of cell staining for HER2 and intensity scores are: negative; 1+; 2+ and 3+ using breast cancer standard arrays as a guide for intensity at least 3 grade 3 CIRS-G comorbidities OR No peripheral edema >= grade 2 at baseline All irAEs while receiving prior immunotherapy must have resolved to ? grade 1 or Baseline prior to Screening for this study. Must not have experienced a ? grade 3 immune-related AE within the past 16 weeks or any grade 4 life- threatening irAE (regardless of duration) or neurologic or ocular AE of any grade while receiving prior immunotherapy (NOTE: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy, but must have no history of adrenal crisis and be asymptomatic) - Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose Participants must be otherwise indicated for radiation therapy independent of this study:\r\n* For low-grade gliomas, typical indications would include at least one of:\r\n** Progressive or recurrent disease as defined by imaging\r\n** Persistence or progression of neurological symptoms (e.g., seizures), or\r\n** At risk of early progression as defined by either (a) age >= 40, (b) mindbomb homolog 1 (MIB-1) >= 3%, or (c) size > 6 cm and/or of limited resectability\r\n* For favorable grade III gliomas, typical indications would be at upfront diagnosis following maximal safe surgery or a recurrence of a lower grade tumor with metaplastic evolution to grade III disease Pap test documenting atypical squamous cells of undetermined significance (ASCUS)/HPV+, atypical squamous cells high grade (ASC-H), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL) within 4 months prior to screening Visit 1; Patients with the following histologies: \r\n* Diffuse astrocytoma (grade 2)\r\n* Oligodendrogliomas (any grade)\r\n* Pleomorphic xanthoastrocytoma (PXA, any grade) Patients must have a creatinine and AST =< grade 1 AST =< grade 1 Subjects who experienced grade 3 or 4 toxicity regardless of causality to the cell infusion must have had a reduction to a grade 1 or less or returned to baseline levels < Grade 2 hypo/hyperkalemia < Grade 3 hypo/hyperphosphatemia < Grade 3 hypo/hypermagnesemia Any grade T1 papillary disease OR Known persistent (> 4 weeks) ? Grade 2 neutropenia, ? Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy Grade 3b FL Must not have experienced a ? Grade 3 AE or neurologic or ocular AE of any grade while receiving prior immunotherapy Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of first dose Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization. Sodium levels =< grade 1 Grade >1 retinopathy EXPANSION COHORT ONLY: Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE version 4.0 =< grade 1 except neuropathy (=< grade 2) and tinnitus (=< grade 2), and hearing loss (=< grade 4) Patients must not have a history of grade >= 2 neurological toxicity with previous treatment, or persistent grade >= 2 peripheral neuropathy; drowsiness and lethargy were exempted from this criteria unless previously persistent for more than one week Grade >1 retinopathy Toxicity recovery should include the following:\r\n* Grade =< 2 neuropathy\r\n* Grade =< 2 diarrhea\r\n* Grade =< 2 mucositis Known grade 3 or 4 neurotoxicity Peripheral edema > grade 1 Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 as below:\r\n* Grade 0: Up and about, no restriction\r\n* Grade 1: Ambulatory, no strenuous activity\r\n* Grade 2: Ambulatory, capable of self-care appropriate for age; up and about > 50% of time, but unable to carry out any physical activities or attend school\r\n* Grade 3: Limited self-care only; up and about < 50% of time\r\n* Grade 4: Disabled, no self-care; bedridden or confined to chair Hypertriglyceridemia >= Grade 2 Hyperglycemia (fasting) >= Grade 2 Grade 3b FL Histologically documented FL (Grade 1, 2 and 3A) High grade (or grade 3) serous histology or known to have gBRCAmut Persistent grade 2 fatigue at Baseline. Peripheral edema ? grade 2 within 2 weeks prior to study day 1. Grade >=2 hypercholesterolemia or hypertriglyceridemia Baseline peripheral edema >= grade 3 Significant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14 days prior to first dose Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before study treatment Grade 3b FL Grade >=2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia Has not recovered (ie, to ? Grade 1 or to baseline) from chemotherapy induced AEs. Note: Patient with ? Grade 1 neuropathy or ? Grade 2 alopecia is an exception to this criterion and may qualify for the study. Persistent > Grade 2 toxicity from prior cancer therapy Has not recovered (ie, to ? Grade 1 or to baseline) from chemotherapy induced AEs. Note: Patient with ? Grade 1 neuropathy or ? Grade 2 alopecia is an exception to this criterion and may qualify for the study. Persistent > Grade 2 toxicity from prior cancer therapy Serum creatinine level greater than CTC grade 2. No significant immune-related adverse event due to the nivolumab plus ipilimumab dose received in the neoadjuvant setting, as follows:\r\n* Any grade myocarditis, including an asymptomatic troponin elevation felt to be related to nivolumab plus ipilimumab\r\n* Any grade neurologic complication (e.g. meningitis, encephalitis, neuropathy); study chair should be contacted if there is any question whether an adverse event (AE) was neurologic in nature\r\n* Grade 2 or higher pneumonitis\r\n* Grade 2 colitis\r\n* Grade 2 or higher anemia (due to drug; unrelated anemia is not exclusionary)\r\n* Thyroid/adrenal AEs regardless of grade that have stabilized or are clinically asymptomatic are eligible\r\n* Fatigue, regardless of grade, is not a contraindication to randomization\r\n* Grade 4 AST or ALT elevation\r\n* Asymptomatic elevated amylase and lipase, regardless of grade, are not contraindications to randomization\r\n* Grade 4 rash; grade 3 rash is not a contraindication to randomization; any oropharyngeal lesions or bullous skin lesions that are suggestive of toxic epidermal necrolysis or Stevens-Johnson syndrome are contraindications to randomization regardless of the grade of rash\r\n** If not specified above, other Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher AEs deemed possibly related to the nivolumab plus ipilimumab are exclusions to randomization; AEs that were attributable to surgery or adjuvant RT would not be contraindications to randomization Any tumor grade At least a fifth grade education Histologically confirmed BE with high grade dysplasia, invasive carcinoma of the esophagus, low grade dysplasia Must have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified Radiation Therapy Oncology Group (RTOG) scale:\r\n* Grade 0 – None\r\n* Grade 1 – Slight dryness of mouth (good response on stimulation and no significant dietary alterations necessary)\r\n* Grade 2 – Moderate dryness of mouth (poor response on stimulation and altered oral intake required such as frequent water, oral lubricants, or soft-moist foods)\r\n* Grade 3 – Complete dryness of mouth (no response on stimulation and difficult oral alimentation; intravenous (IV) fluids, pureed diet or tube feedings may be required)\r\n* Grade 4 – Fibrosis Grade 3 disease Patients on adjuvant ipilimumab are allowed to participate at least 30 days from drug discontinuation as long as they have at most grade 1 adverse events (or grade 2 if they have to received hormone replacement therapy for their otherwise grade 1 ipilimumab-induced autoimmune endocrinopathies) Subjects with a history of low or high grade dysplasia No significant esophagitis (LA grade < B, C and D). Significant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior cycle 1, day 1 Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment Significant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to screening Significant neuropathy (grades 3–4, or grade 2 with pain) within 21 days prior to registration Significant neuropathy (grades 2 or grade 1 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3–4, or grade 2 with pain) Must not have any significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrollment. Significant neuropathy (grades 3 to 4 or grade 2 pain) Significant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to randomization Patients who have experienced significant neuropathy (grades 3-4 or grade 2 with pain) within 14 days prior to registration are NOT eligible for participation Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to the first day of treatment No significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to cycle 1 day 1 Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to signing consent Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollment Significant neuropathy (grades 3 to 4, or grade 2 pain) Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to randomization Significant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to randomization Significant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days prior to randomization. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollment Grade >= 2 neuropathy Baseline neuropathy of > grade 2 SAFETY RUN-IN: Patients with baseline grade 2 neuropathy >= grade 3 neuropathy at the time of enrollment Neuropathy > grade 1 CTCAE Grade > 2 neuropathy Neurosensory neuropathy > grade 2 at baseline. Neuropathy ? Grade 2. Patients with a history of grade >= 2 neuropathy Patients with >= grade 2 neuropathy Significant neuropathy > grade 2 at the time of first dose or within 14 days of enrollment Neuropathy > grade 1 Patients with any baseline grade 2 neuropathy Grade 3 baseline neuropathy Neuropathy: patients must have =< grade 1 neuropathy at enrollment Neuropathy =< grade 1 at the time of registration Diabetic neuropathy (any grade) Neuropathy grade >1 Neuropathy >= grade 1 Patient has baseline neuropathy of >= grade 2 Significant neuropathy (grade 3, grade 4) at the time of the first dose and/or within 14 days before enrollment Neuropathy > Grade 1 Neuropathy (?grade 2 CTCAE) Patients with >= grade 2 neuropathy No grade >= 2 neuropathy Ongoing grade >= 3 neuropathy Baseline neuropathy > grade 1 Patient has baseline neuropathy of > grade 2 Neuropathy Grade > 3 Grade <= 2 neuropathy Neurosensory neuropathy ? grade 2 at baseline. Neuropathy CTCAE grade > 2 Patients with > grade 1 neuropathy Subjects with >= grade 2 neuropathy Evidence of ? Grade 2 neuropathy Neuropathy > Grade 1. Patients with symptomatic neuropathy Patients with >= grade 2 neuropathy Significant neuropathy (? Grade 3) within the 14 days prior to randomization Subjects with >= grade 2 neuropathy Neurosensory neuropathy ? grade 2 at baseline Significant neuropathy >= grade 3 or grade 2 neuropathy with pain at baseline Significant neuropathy >= grade 3 or grade 2 neuropathy with pain at baseline > Grade 3 neuropathy Grade >1 neuropathy History of Grade ?2 neuropathy Patient has baseline neuropathy of >= grade 2 Neuropathy > grade 2 Significant neuropathy >= grade 3 or grade 2 neuropathy with pain at baseline ? Grade-2 neuropathy No current grade 2, 3, or 4 of neuropathy Patients with any neuropathy > Grade 1 Clinical evidence of neuropathy Significant neuropathy >= grade 3 at baseline Patients with any neuropathy. Patients with neuropathy > grade 1 Subject has Neuropathy ? Grade 2 at Screening. With < or = grade 2 neuropathy > grade 2 neuropathy Patients with grade III-IV neuropathy Grade 2 or above neuropathy Presence of ? Grade 2 neuropathy. Neuropathy Grade 3 or more Grade >= 2 neuropathy Neuropathy >= grade 2 (moderate neuropathy that limits instrumental activities of daily living) Subject has ? CTCAE v4.03 Grade 2 neuropathy. Neuropathy: no baseline neuropathy grade > 2 Known diabetic neuropathy Greater than Grade 2 neuropathy or ? Grade 2 neuropathy with pain at baseline, regardless of whether or not the patient is currently receiving medication Has neuropathy ? Grade 2.